Novartis bolsters Fabhalta data in competition with AstraZenecanews2024-12-06T17:45:30+00:00December 6th, 2024|Endpoints News|
AstraZeneca and Daiichi report pooled ADC data in mutant lung cancernews2024-12-06T12:10:04+00:00December 6th, 2024|Endpoints News|
BioNTech, DualityBio report promising ADC data in solid tumorsnews2024-12-06T11:41:05+00:00December 6th, 2024|Endpoints News|
Biosecure compromise could add review process for named companies, sources saynews2024-12-05T19:18:15+00:00December 5th, 2024|Endpoints News|
Protara’s stock nearly doubles as biotech divulges new bladder cancer datanews2024-12-05T16:33:33+00:00December 5th, 2024|Endpoints News|
Merck’s Eliav Barr on its LaNova deal and the unknowns of VEGF bispecificsnews2024-12-05T16:31:56+00:00December 5th, 2024|Endpoints News|
CG Oncology’s bladder cancer treatment shows durability potential in Phase 3news2024-12-05T12:00:07+00:00December 5th, 2024|Endpoints News|
Moderna defends pandemic prep as vaccine skeptics gain powernews2024-12-04T19:45:27+00:00December 4th, 2024|Endpoints News|
Relmada’s rapid-acting NMDA depression drug expected to fail second Phase 3news2024-12-04T15:31:36+00:00December 4th, 2024|Endpoints News|
GeneDx bets that rare disease data can aid drug discoverynews2024-12-04T15:00:09+00:00December 4th, 2024|Endpoints News|
